Evidence map›Paper›PMID 34651222›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2022

Pharmacokinetic and pharmacodynamic assessment of histamine H

Yasuyuki Kimura, Keisuke Takahata, Toshiharu Shimazaki, Soichiro Kitamura, Chie Seki, Yoko Ikoma, Masanori Ichise, Kazunori Kawamura, Makiko Yamada, Ming-Rong Zhang and 3 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04631276 (Clinical Study on Histamine H3 Receptor Occupancy of TS-091 by PET Examination in Healthy Adult Subjects), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04631276 phase1completednot on this map

Clinical Study on Histamine H3 Receptor Occupancy of TS-091 by PET Examination in Healthy Adult Subjects

TypeinterventionalSponsorTaisho Pharmaceutical Co., Ltd.Ran2014 to 2015Enrolled12ConditionsHealthy SubjectsArmsTS-091
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Development and Preclinical Characterization of [Journal of medicinal chemistry · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Yasuyuki KimuraDepartment of Functional Brain Imaging, Institute for Quantum Medical Science , National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba, Chiba, 263-8555, Japan.ORCID http://orcid.org/0000-0002-7927-9483
Keisuke TakahataDepartment of Functional Brain Imaging, Institute for Quantum Medical Science , National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba, Chiba, 263-8555, Japan.
Toshiharu ShimazakiTaisho Pharmaceutical Co, Ltd. 3-24-1 Takada, Toshima-ku, Tokyo, 170-8633, Japan.
Soichiro KitamuraDepartment of Functional Brain Imaging, Institute for Quantum Medical Science , National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba, Chiba, 263-8555, Japan.
Chie SekiDepartment of Functional Brain Imaging, Institute for Quantum Medical Science , National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba, Chiba, 263-8555, Japan.
Yoko IkomaDepartment of Molecular Imaging and Theranostics, Institute for Quantum Medical Science , National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba, 263-8555, Japan.
Masanori IchiseDepartment of Functional Brain Imaging, Institute for Quantum Medical Science , National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba, Chiba, 263-8555, Japan.
Kazunori KawamuraDepartment of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science , National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage, Chiba, Chiba, 263-8555, Japan.
Makiko YamadaDepartment of Functional Brain Imaging, Institute for Quantum Medical Science , National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba, Chiba, 263-8555, Japan.
Ming-Rong ZhangDepartment of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science , National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage, Chiba, Chiba, 263-8555, Japan.
Makoto HiguchiDepartment of Functional Brain Imaging, Institute for Quantum Medical Science , National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba, Chiba, 263-8555, Japan. higuchi.makoto@qst.go.jp.
Izumi NishinoTaisho Pharmaceutical Co, Ltd. 3-24-1 Takada, Toshima-ku, Tokyo, 170-8633, Japan.
Tetsuya SuharaDepartment of Functional Brain Imaging, Institute for Quantum Medical Science , National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba, Chiba, 263-8555, Japan.
National Institutes for Quantum Science and Technology · JPTaisho Pharmaceutical (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeHistamine H

methodsTo measure the histamine H

resultsAdministration of enerisant hydrochloride decreased the radioligand binding in a dose-dependent manner. The estimated receptor occupancy values at 2 h varied as a function of its dose or plasma concentration. The time course of the occupancy showed persistently high levels (> 85%) in the two subjects with higher doses (25 and 12.5 mg). The occupancy was also initially high at 2 h and 6 h with the lower dose of 5 mg, but it decreased to 69.7% at 26 h.

conclusionThe target engagement of enerisant was demonstrated in the brains of living human subjects. The occupancy of histamine H

trial registrationThis study was retrospectively registered with ClinicalTrials.gov (NCT04631276) on November 17, 2020.

Indexed as

NarcolepsyNeuroprotective AgentsReceptors, Histamine H3Sleep Initiation and Maintenance DisordersBrainHistamineHumansLigandsMaleNiacinamidePositron-Emission TomographyPyridinesQuinolonesHistamineLigandsNeuroprotective AgentsNiacinamidePyridinesQuinolonesReceptors, Histamine H3TASP457EnerisantHistamine H3 receptorsHysteresisPositron emission tomographyReceptor occupancy

Identifiers

PMID34651222
OpenAlexW3206669669

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.